SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Data Sheet (Cat.No.T4535)

TargetMol

Etomoxir sodium salt

Chemical Properties



CAS No. :	828934-41-4
Formula:	C15H18ClO4.Na
Molecular Weight:	320.74
Appearance:	no data available
Storage:	store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Etomoxir sodium salt ((R)-Etomoxir sodium salt) is a carnitine palmitoyltransferase 1a (CPT-1a) inhibitor that blocks fatty acid synthesis. Etomoxir sodium salt has antitumor activity.
Targets(IC50)	Apoptosis,Others
In vitro	**METHODS**: BCa cell lines UM-UC-3 and T24 were treated with Etomoxir sodium salt (20-200 μM) for 24-72 h. Cell viability was examined using MTT. **RESULTS**: Etomoxir inhibited the viability of UM-UC-3 and T24 cells in a dose-dependent manner. [1] **METHODS**: Human breast cancer cells MCF-7 and T47D were treated with Etomoxir sodium salt (0.1-50 μM) for 24 h. Cellular FAO activity was measured by 3H palmitic acid. **RESULTS**: Low micromolar concentrations of Etomoxir were sufficient to achieve maximal inhibition of FAO in MCF-7 and T47D cells. [2]
In vivo	**METHODS**: To test the antitumor activity in vivo, Etomoxir sodium salt (40 mg/kg) was intraperitoneally injected into BALB/c nude mice carrying human bladder cancer tumor T24 every two days for twenty days. **RESULTS**: Etomoxir significantly inhibited tumor growth. [1] **METHODS**: To test the activity against multiple sclerosis, Etomoxir sodium salt (15 mg/kg) was intraperitoneally injected into a C57BL/6J mouse model of EAE induction once a week or every two days for two weeks. **RESULTS**: Etomoxir-treated mice showed reduced disease severity as well as reduced inflammation and demyelination. Disruption of fatty acid metabolism promotes downregulation of CNS inflammation and this metabolic pathway is a potential therapeutic target for multiple sclerosis. [3]

Solubility Information

Solubility	DMSO: 3.21 mg/mL (10 mM),Sonication is recommended. Saline: 3.5 mg/mL H2O: 5 mg/mL (15.59 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.1178 mL	15.589 mL	31.1779 mL
5 mM	0.6236 mL	3.1178 mL	6.2356 mL
10 mM	0.3118 mL	1.5589 mL	3.1178 mL
50 mM	0.0624 mL	0.3118 mL	0.6236 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Huang D, Chowdhury S, Wang H, et al. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Reports Medicine. 2021, 2(12): 100471.